Monday, February 16, 2015

Diplomat to dispense FDA-approved IBRANCE (palbociclib) to treat metastatic breast cancer



Palbociclib.svg


In continuation of my update on letrozole

The approval for IBRANCE® -(Palbociclib) came more than two months ahead of schedule, through the FDA's Breakthrough Therapy designation and Priority Review programs. According to Pfizer, the registration trial showed that, compared to letrozole alone, IBRANCE® in combination with letrozole nearly doubled the time before tumors progressed. The drug is the first in a new class of anti-cancer agents, CDK 4/6 inhibitors, to be FDA-approved.

"IBRANCE® offers hope for the breast cancer community, and we're excited to be able to offer it at Diplomat," said Gary Kadlec, president of the company. "Patients facing metastatic breast cancer need the support of advancements like these, and we are honored to complement this treatment with focused care."

IBRANCE® is indicated for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

Thursday, February 5, 2015

Newly found peptide may reduce desire for food



We know that, Pituitary adenylate cyclase-activating polypeptide also known as PACAP is a protein that in humans is encoded by theADCYAP1 gene. PACAP is similar to vasoactive intestinal peptide. One of its effects is to stimulate enterochromaffin-like cells. It binds to vasoactive intestinal peptide receptor and to the PACAP receptor.

Newly found protein in naked mole rat helps ward off cancer

Newly found protein in naked mole rat helps ward off cancer